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Editorial on the Research Topic
Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer
The use of radical prostatectomy in patients with high risk of recurrence has significantly increased 
during the past 10  years (1). Thus, adjuvant radiation as a part of multimodality treatment or 
salvage radiation at the evidence of prostate-specific antigen (PSA) progression represents mainstay 
curative-intent options for a great number of prostate cancer patients. Although, few randomized 
trials and many retrospective studies have been published, many uncertainties still mold the 
discussions on the best treatment management for men after prostatectomy. This research topic 
(https://www.frontiersin.org/research-topics/3739/controversies-and-perspectives-in-the-use-of-
postoperative-radiotherapy-for-prostate-cancer) successfully intended to foster discussions on 
current controversies in the use of postoperative radiotherapy and to present novel perspectives 
for treatment optimization.
Several randomized trials have shown that dose intensification in the primary treatment of 
prostate cancer improves local control. However, the data are scarcer in the postoperative setting. 
Beck et al. review the literature and present the only randomized phase III trial addressing dose-
intensified salvage radiotherapy (64 vs. 70 Gy), SAKK (Swiss Group for Clinical Cancer Research) 
09/10 (2). Recent publication showed that acute toxicity (gastrointestinal and urinary) and early 
quality of life data were not significantly different between the two treatment arms; however, 
a significant worsening of urinary quality of life was noted in the 70-Gy arm. The primary endpoint 
analysis (biochemical relapse free survival) and long-term endpoints are eagerly awaited.
Potential overtreatment and/or radiation-related toxicity with subsequent impact on patient’s 
quality of life are common arguments for withdrawing or deferring postoperative radiotherapy 
by urologists. By revealing gaps between evidence and clinical practice, Raziee et al. (Raziee and 
Berlin) claim that concerns with toxicities and/or quality of life should not preclude the utilization 
of curative-intent postoperative radiotherapy. Also, Herrera and Berthold review level I evidence on 
adjuvant radiotherapy that demonstrates improvements in biochemical progression-free survival, 
clinical progression-free survival, and overall survival in patients with high-risk pathological features 
(Herrera and Berthold). However, they point out that offering immediate adjuvant radiotherapy to 
all men with high-risk features would overtreat around 50% of men who would anyway be cancer-
free, exposing them to unnecessary toxicity and adding important costs to the health-care system. 
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The assessment of adjuvant versus early salvage radiation is being 
addressed in important randomized trials to be published in the 
forthcoming years (Radiotherapy and Androgen Deprivation 
in Combination After Local Surgery, Radiotherapy–Adjuvant 
versus Early Salvage, and Groupe d’ Étude des Tumeurs Uro-
Génitales) [Raziee and Berlin; Herrera and Berthold].
The role of ADT in combination with primary radiotherapy 
for intermediate- and high-risk prostate cancer is well estab-
lished. Recently, two prospective phase III trials (RTOG 9601 
and GETUG-16) have shown improvements in disease outcomes 
when ADT is combined with salvage radiotherapy (3, 4). However, 
in the setting of early salvage, the role of ADT remains debat-
able. In patients with pre-SRT PSA <0.7 ng/ml, which comprised 
>50% of the RTOG 9601 study population, the addition of ADT 
provided no improvement in overall survival or metastasis-free 
survival. ADT is not devoid of important side effects, and many 
questions are still open on which patients benefit the most, ADT 
type, and treatment duration.
In parallel, the impact of the increasing aging population on 
the worldwide burden of cancer is well known, and the man-
agement of prostate cancer in the elderly is a topic of utmost 
importance. Goineau et  al. specifically shed light on the care 
of elderly patients with prostate cancer after prostatectomy. 
The authors propose a decision tree based on the International 
Society of Geriatric Oncology recommendations.
Novel imaging modalities are reshaping the use of postop-
erative radiotherapy in prostate cancer patients. Molecular 
imaging has provided increasing accuracy in the localization of 
recurrence, and it has progressively changed clinical practice. 
Novel imaging tools can define the site of the recurrence and 
the extent of disease and thus individualize salvage treatments. 
In this research topic, Amzalag et  al. comprehensively review 
most important novel targeted tracers for the evaluation of 
recurrent disease.
Analyses of large multi-institutional retrospective series 
along with predictive nomograms have importantly helped 
clinicians to estimate individual patient’s risks and tailor treat-
ment decisions (5, 6). More lately, genomic classifiers have been 
added to the armamentarium of clinicopathological parameters 
and novel imaging modalities, representing an emerging tool 
able to provide exciting prognostic information for patients 
with recurrent disease (7–10). A better identification of patients 
with indolent and more aggressive tumors will help to select 
which patients may derive the greatest benefits from treatment 
intensification or deintensification and thus reducing therapy-
associated costs and unnecessary adverse effects.
In terms of radiotherapy technique, important variability 
in the delineation of the prostate bed is observed. At least four 
international contouring consensus guidelines are available, 
but present discrepancies in target definition. This is a relevant 
topic when comparing outcome data from different retrospec-
tive and prospective cohorts. Latorzeff et al. from the GETUG 
group highlight some controversies to help clinicians create 
an appropriate volume delineation of the prostate bed in the 
setting of adjuvant and salvage radiotherapy (Latorzeff et al.). 
Also addressing variability in contour delineation, Delpon 
et al. critically report on automated atlas-based segmentation 
algorithms (Delpon et  al.). The authors compare different 
commercially available options that could assist radiation 
oncologists in potentially improving contour delineation. Not 
to mention on the unclear benefits of elective treatment of 
the pelvic nodes which is currently addressed in the ongoing 
RTOG 0534 trial.
Image-guided radiotherapy is a key advancement in modern 
radiotherapy to decrease normal tissue toxicity. Vilotte et  al. 
reviewed the literature on image guidance techniques in the 
postoperative setting (Vilotte et  al.). The authors highlight key 
points on different techniques applicable to the prostatic bed and 
discuss potential reductions in planning target volume margins 
to reduce treatment complications.
By using an innovative approach for locally advanced tumors 
with high risk of local recurrence, Buge et al. present a preclinical 
evaluation of intraoperative low-energy photon radiotherapy 
using spherical applicators. With cadaveric models assessed by 
MRI, the authors show that intraoperative radiotherapy of the 
prostate bed is feasible, with good coverage of targeted tissues, 
and is potentially able to replace external beam radiotherapy in 
the future. Clinical studies are warranted to validate this exciting 
approach that could further decrease normal tissue toxicity.
Finally, in view of current and evolving data, the use of 
postoperative radiotherapy should be made in the context 
of a multidisciplinary discussion on treatment benefits and 
potential risk of side effects. Patients should take a proactive 
role in the decision-making process with unbiased, transpar-
ent, and evidence-based information. New imaging modalities 
and commercially available biomarkers have been increasingly 
utilized in the clinic, but unfortunately have not been timely 
incorporated into prospective studies. This dissonance between 
novel tools and lack of robust validation is a destiny not only 
in Radiation Oncology but also in other disciplines with 
rapidly evolving technologies. Hopefully, all this progress will 
ultimately lead to improvements in outcomes that matter most 
to our patients.
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